Dosage guide · 20 mg vial

Livagen Dosage Protocol

Lys-Glu-Asp-Ala (KEDA) · tetrapeptide bioregulator

The reference protocol uses 500 mcg daily for weeks 1–2, rising by 500 mcg every 2 weeks to 2 mg daily from week 7. With 3 mL bacteriostatic water, a 20 mg vial is 6.67 mg/mL, so the 500 mcg start amount measures 7.5 units (0.075 mL) on a U-100 syringe.

How oftenOnce daily

Starting dose0.5 mg

Start = units7.5 units

Mix3 mL BAC water

Reviewed 25 Oct 2026 · Education only, not medical advice

Livagen 20 mg vial

Not currently stocked by Peak Peptides Australia

No product photo — this strength isn't stocked by Peak

Dosage chart How to mix Supplies Calculator About Livagen References

01 · DOSAGE CHART

Livagen dosage chart

Gradual daily approach · 20 mg vial + 3 mL BAC water

BAC water added

Concentration6.67 mg/mL

1 unit (U-100)66.7 mcg= 0.01 mL

How oftenOnce dailySubcutaneous injection

3 mL is the mix used by the attributed 20 mg reference protocol, giving 6.67 mg/mL and 7.5 units for 500 mcg.

Livagen dosage chart for a 20 mg vial mixed with 3 mL of bacteriostatic water
Week	Daily dose	Syringe units
Weeks 1–2Start	0.5 mg	7.5 units0.075 mL
Weeks 3–4	1 mg	15 units0.15 mL
Weeks 5–6	1.5 mg	22.5 units0.225 mL
Weeks 7–12Maintenance	2 mg	30 units0.3 mL

Once daily · any consistent time · subcutaneous injection

The attributed protocol increases by 500 mcg every 2 weeks through week 6.

It describes an 8–12 week course, with an optional extension to 16 weeks.

Reference-site amounts only — Livagen has no clinically established human dose and is not an approved medicine in Australia. Education only, not medical advice. Dose amounts adapted from Livagen 20 mg vial dosage protocol (PeptideDosages.com); units are recalculated for the vial and mix selected above.

02 · HOW TO MIX

Mixing a 20 mg vial with 3 mL of BAC water

Using a 1 mL (100-unit) insulin syringe, 3 full draws of bacteriostatic water gives 6.67 mg/mL.

1
Add the water slowly
Wipe both rubber stoppers with an alcohol swab and let them dry. Draw 3 mL of bacteriostatic water and let it run slowly down the inside of the vial wall — not straight onto the powder.
2
Swirl gently
Swirl or roll the vial gently until the powder has dissolved. Give it a few minutes to settle if needed.
3
Don't shake it
Shaking can damage the peptide and cause foaming. Gentle swirling only.
4
Check it's fully clear
Only use it once it is fully clear with no particles. Label the vial with the date and 6.67 mg/mL, then store it in the fridge at 2–8 °C.

Full illustrated reconstitution guide

03 · SUPPLIES NEEDED

What you'll need

Counts follow the dosage chart above at the highest amount in each step, using a 20 mg vial mixed with 3 mL.

Length of protocol

4Livagen 20 mg vials70 mg needed in total

601 mL insulin syringesU-100, 27–31G · one per draw + one per vial mixed

2BAC water 10 mL bottles12 mL used for mixing

120Alcohol swabsSkin + stopper, every time

Plus an approved sharps container. Syringes and swabs are sold by Australian pharmacies — Peak Peptides and Pure Performance supply the bacteriostatic water.

Peak Peptides Australia Bacteriostatic water 10 mL

Bacteriostatic water 10 mLPeak Peptides Australia

Pure Performance Australia Bacteriostatic water 10 mL

Bacteriostatic water 10 mLPure Performance Australia

04 · CALCULATOR

Check a different amount

Enter your vial, water and dose to see the matching syringe units.

Concentration Calculator

Labelled Vial Amount (mg)

Verified Final Liquid Volume3 mL

Amount to Evaluate (not a recommendation)

Concentration

6.67 mg/mL

(6667 mcg/mL)

Calculated Liquid Volume

0.075 mL

Equivalent U-100 volume scale position

7.5markings (not biological IU)

Illustration of a U-100 volume scale, not preparation or injection guidance

05 · PROTOCOL DETAILS

About Livagen

Protocol overview

Starting dose: 500 mcg once daily in weeks 1–2
How it increases: 1 mg in weeks 3–4, 1.5 mg in weeks 5–6, then 2 mg
Frequency: Once daily
When to take it: Any consistent time of day
Course length: 8–12 weeks; the source notes an optional extension to 16 weeks
Common mix: 3 mL bacteriostatic water → 6.67 mg/mL

Storage

Before mixing: The attributed protocol says to keep lyophilised material at −20 °C in dry, dark conditions.
After mixing: The attributed protocol says to refrigerate at 2–8 °C, protected from light.
Never: Avoid repeated freeze–thaw cycles or using a vial that is cloudy or has particles.

How it works

Livagen is the synthetic tetrapeptide Lys-Glu-Asp-Ala, also called KEDA. It is described as a short peptide bioregulator, but that label does not establish a therapeutic effect in people.

In vitro, Livagen inhibited enkephalin-degrading enzymes in human serum; the reported half-maximal inhibitory concentration was 20 μM. It did not bind mu or delta opioid receptors in rat brain membrane preparations in that experiment.

Cell and animal experiments reported changes in rat liver-culture morphology and protein synthesis. Those models cannot show that Livagen treats liver disease or improves liver function in people.

Illustrated mechanism explainer

What the research shows

A 2003 in-vitro experiment reported a Livagen IC50 of 20 μM for inhibition of enkephalin-degrading enzymes in human serum; it was not a clinical dosing or outcomes study.
In a 2005 rat experiment, two weeks of oral Livagen changed digestive-enzyme activity; the paper also reported a 50% reduction of one small-intestine dipeptidase activity in vitro. This does not establish effects of injected Livagen in people.
A 2001 cell-culture experiment used rat hepatocytes from animals aged 1 to 24 months and reported increased protein synthesis, with the largest reported effect in cells from older rats.
ClinicalTrials.gov API searches for both Livagen and Lys-Glu-Asp-Ala returned no study records when checked in October 2026. No clinically established human dose was identified.
Livagen is not an approved medicine in Australia. TGA says goods not on the ARTG have not been assessed by it for safety, quality or effectiveness.

Reported side effects

No human clinical safety study or established human side-effect rate was identified in the ClinicalTrials.gov searches, so safety after subcutaneous use is unknown.
The 2005 animal paper administered Livagen orally for two weeks, not by subcutaneous injection; it cannot quantify injection-related reactions or human adverse effects.
TGA states that unapproved therapeutic goods have not been assessed for safety, quality or effectiveness, so product identity, potency and sterility cannot be assumed.

Important notes

Livagen is not an approved medicine in Australia; the TGA advises that unapproved goods have not been assessed for safety, quality or effectiveness.
WADA's 2026 List does not name Livagen or AEDL, but S0 prohibits at all times any pharmacological substance with no current approval by a governmental regulatory health authority. Athletes should obtain written anti-doping advice before use.
The amounts in the chart are copied from a reference-site educational protocol, not from a human clinical dose-finding study.
Never use a mixed vial that is cloudy or has particles in it.

Injection basics

Use a new sterile 1 mL (100-unit) U-100 insulin syringe, 27–31G, every time — never reuse or share.
Wipe the vial stopper and the skin with an alcohol swab and let both dry first.
Inject under the skin (subcutaneously) of the abdomen, thigh or upper arm, and rotate sites.
Put used syringes straight into an approved sharps container — the NDSS lists Australian disposal options.

Guidance: World Health Organization · National Diabetes Services Scheme (NDSS)

06 · QUICK ANSWERS